Ark Biosciences and KOLs Published a Review Paper on Antiviral Drug Resistance Across Chronic and Acute Infections
Antiviral therapy can lead to drug resistance, but multiple factors determine the frequency of drug resistance mutations and the clinical consequences...
know more >
Ark Biosciences and Calibr Announce Joint Development of First-in-Class Chronic Obstructive Pulmonary Disease Drug
Ark announced a collaboration with the Calibr to jointly develop novel first-in-class drugs for the treatment of Chronic Obstructive Pulmonary Disease (COPD) and related lung diseases...
know more >
Ark Biosciences Initiates VICTOR Study
Ark Biosciences announced that dosing with AK0529, its leading antiviral drug against respiratory syncytial virus (RSV), has commenced in infants hospitalized with RSV infection in the VICTOR study...
know more >
Ark Biosciences' Anti-RSV AK0529 Successfully Completes Phase I Study
Ark Biosciences announced the successful completion of phase 1 clinical study of its anti-respiratory syncytial virus (RSV) drug AK0529...
know more >
Ark Biosciences Completes Series A Financing and Reports Significant Progress for AK0529
Ark Biosciences announced successful completion of a Series A financing...
know more >